Psychotropic medications, self-harm behavior, and eating disorders

Self-Harm Behavior and Eating Disorders: Dynamics, Assessment, and Treatment

Volumn , Issue , 2005, Pages 245-257

  Sansone, Randy A ^a,b   Levitt, John L ^c   Sansone, Lori A ^d  

^a WRIGHT STATE UNIVERSITY   (United States)

^b KETTERING MEDICAL CENTER   (United States)

^c Alexian Brothers Behavioral Health Hospital   (United States)

^d Private practice with Premier Healthnet   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 12744257356     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.4324/9780203017913-25     Document Type: Chapter

References (53)

1. Ad-Dab’bagh, Y., Greenfield, B., Milne-Smith, J., & Freedman, H. (2000). Inpatient treatment of severe disruptive behaviour disorders with risperidone and milieu therapy. Canadian Journal of Psychiatry, 45, 376-382.
2. Bendetti, F., Sforzini, L., Colombo, C., Marrei, C., & Smeraldi, E. (1998). Low-dose clozapine in acute and continuation treatment of severe borderline personality disorder. Journal of Clinical Psychiatry, 59, 103-107.
3. Berger, P. A. (1987). Pharmacological treatment for borderline personality disorder. Bulletin of the Menninger Clinic, 51, 277-284.
4. Bergmann, F., Bleich, S., Wischer, S., & Paulus, W. (2002). Seizure and cardiac arrest during bupropion SR treatment. Journal of Clinical Psychopharmacology, 22, 630-631.
5. Bourin, M. (1999). Psychopharmacological profile of venlafaxine. Encephale, 25, 21-25.
6. Brinkley, J. R. (1993). Pharmacotherapy of borderline states. Psychiatric Clinics of North America, 16, 853-884.
7. Buckley, N. A., & McManus, P. R. (2002). Fatal toxicity of serotoninergic and other antidepressant drugs: Analysis of United Kingdom mortality data. British Medical Journal, 325, 1332-1333.
8. Calabrese, J. R., Shelton, M. D., Rapport, D. J., & Kimmel, S. E. (2002). Bipolar disorders and the effectiveness of novel anticonvulsants. Journal of Clinical Psychiatry, 63, 5-9.
9. Chengappa, K. N. R., Baker, R. W., & Sirri, C. (1995). The successful use of clozapine in ameliorating severe self-mutilation in a patient with borderline personality disorder. Journal of Personality Disorders, 9, 76-82.
10. Chengappa, K. N. R., Ebeling, T., Kang, J.S., Levine, J., & Parepally, H. (1999). Clozapine reduces severe self-mutilation and aggression in psychotic patients with borderline personality disorder. Journal of Clinical Psychiatry, 60, 477-484.
11. Coccaro, E. F. (1998). Clinical outcome of psychopharmacologic treatment of borderline and schizotypal personality disordered subjects. Journal of Clinical Psychiatry, 59, 30-35.
12. Coons, P. M. (1992). The use of carbamazepine for episodic violence in multiple personality disorder and dissociative disorder not otherwise specified: Two additional case reports. Biological Psychiatry, 32, 717-720.
13. Cornelius, J. R., Soloff, P. H., Perel, J. M., & Ulrich, R. F. (1991). A preliminary trial of fluoxetine in refractory borderline patients. Journal of Clinical Psychopharmacology, 11, 116-120.
14. Daly, K. A., & Fatemi, S. H. (1999). Lamotrigine and impulse behaviour. Canadian Journal of Psychiatry, 44, 395-396.
15. Davis, L. L., Ryan, W., Adinoff, B., & Petty, F. (2000). Comprehensive review of the psychiatric uses of valproate. Journal of Clinical Psychopharmacology, 20, 1S-17S.
16. Ekselius, L., & von Knorring, L. (1998). Personality disorder comorbidity with major depression and response to treatment with sertraline or citalopram. International Clinical Psychopharmacology, 13, 205-211.
17. Fava, M., Farabaugh, A. H., Sickinger, A. H., Wright, E., Alpert, J., Sonawalla, S., Nierenberg, A. H., & Worthington, J. J., 3rd. (2002). Personality disorders and depression. Psychological Medicine, 32, 1049-1057.
18. Fava, M., Judge, R., Hoog, S. L., Nilsson, M. E., & Koke, S. C. (2000). Fluoxetine versus sertraline and paroxetine in major depressive disorder: Changes in weight with long-term treatment. Journal of Clinical Psychiatry, 61, 863-867.
19. Gadde, K. M., & Krishnan, K. R. R. (1999). Current status of monoamine oxidase inhibitors in psychiatric practice. The Hatherleigh guide to psychopharmacology (pp. 63-82). New York: Hatherleigh Press.
20. Gardner, D. L., & Cowdry, R. W. (1986). Positive effects of carbamazepine on behavioral dyscontrol in borderline personality disorder. American Journal of Psychiatry, 143, 519-522.
21. Goodnick, P. J. (2001). Ziprasidone: Profile on safety. Expert Opinion on Pharmacotherapy, 2, 1655-1662.
22. Grossman, R. (2002). Psychopharmacologic treatment of patients with borderline personality disorder. Psychiatric Annals, 32, 357-370.
23. Hough, D. W. (2001). Low-dose olanzapine for self-mutilation behavior in patients with borderline personality disorder. Journal of Clinical Psychiatry, 62, 296-297.
24. Kavoussi, R., & Coccaro, E. F. (1999). Pharmacotherapy. In M. Hersen & A. S. Bellack (Eds.), Handbook of comparative interventions for adult disorders (pp. 584-595). New York: Wiley.
25. Khouzam, H. R., & Donnelly, N. J. (1997). Remission of self-mutilation in a patient with borderline personality during risperidone therapy. Journal of Nervous & Mental Disease, 185, 348-349.
26. Koenigsberg, H. W., Woo-Ming, A. M., & Siever, L. J. (2002). Pharmacological treatments for personality disorders. In P. E. Nathan & J. M. Gorman (Eds.), A guide to treatments that work (pp. 625-641). London: Oxford University Press.
27. Liebowitz, M. R., Hollander E., Schneier, F., Campeas, R., Welkowitz, L., Hatterer, J., & Fallon, B. (1990). Reversible and irreversible monoamine oxidase inhibitors in other psychiatric disorders. Acta Psychiatrica Scandinavica, 82, 29-34.
28. Links, P. S., Steiner, M., Boiago, I., & Irwin, D. (1990). Lithium therapy for borderline patients: Preliminary findings. Journal of Personality Disorders, 4, 173-181.
29. Markovitz, P. (1995). Pharmacotherapy of impulsivity, aggression, and related disorders. In E. Hollander & D. J. Stein (Eds.), Impulsivity and aggression (pp. 263-287). New York: John Wiley & Sons.
30. Markovitz, P. J., Calabrese, J. R., Schulz, S. C., & Meltzer, H. Y. (1991). Fluoxetine in the treatment of borderline and schizotypal personality disorders. American Journal of Psychiatry, 148, 1064-1067.
31. Markovitz, P. J., & Wagner, S. C. (1995). Venlafaxine in the treatment of borderline personality disorder. Psychopharmacology Bulletin, 31, 773-777.
32. Mofenson, H. C., Caraccio, T. R., & Greensher, J. (1996). Acute poisonings. In R. E. Rakel (Ed.), Conn’s current therapy (pp. 1149-1194). Philadelphia: W.B. Saunders.
33. Moleman, P., van Dam, K., & Dings, V. (1999). Psychopharmacological treatment of personality disorders. In J. Derksen & C. Maffei (Eds.), Treatment of personality disorders (pp. 207-227). New York: Plenum Publishers.
34. Parker, G. F. (2002). Clozapine and borderline personality disorder. Psychiatric Services, 53, 348-349.
35. Pinto, O. C., & Akiskal, H. S. (1998). Lamotrigine as a promising approach to borderline personality: An open case series without concurrent DSM-IV major mood disorder. Journal of Affective Disorders, 51, 333-343.
36. Power, A. (1998). Drug treatment of depression. Citalopram in overdose may result in serious morbidity and death. British Medical Journal, 316, 307-308.
37. Riesenman, C. (1995). Antidepressant drug interactions and the cytochrome P450 system: A critical appraisal. Pharmacotherapy, 15, 84S-94S.
38. Rinne, T., van den Brink, W., Wouters, L., & van Dyck, R. (2002). SSRI treatment of borderline personality disorder: A randomized, placebo-controlled clinical trial for female patients with borderline personality disorder. American Journal of Psychiatry, 159, 2048-2054.
39. Rocca, P., Marchiaro, L., Cocuzza, E., & Bogetto, F. (2002). Treatment of borderline personality disorder with risperidone. Journal of Clinical Psychiatry, 63, 241-244.
40. Salzman, C., Wolfson, A. N., Schatzberg, A., Looper, J., Henke, R., Albanese, M., et al. (1995). Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. Journal of Clinical Psychopharmacology, 15, 23-29.
41. Sansone, R. A., Wiederman, M. W., & Shrader, J. A. (2000). Naturalistic study of the weight effects of amitriptyline, fluoxetine, and sertraline in an outpatient medical setting. Journal of Clinical Psychopharmacology, 20, 272-274.
42. Sasyniuk, B. I., Jhamandas, V., & Valois, M. (1986). Experimental amitriptyline intoxication: Treatment of cardiac toxicity with sodium bicarbonate. Annals of Emergency Medicine, 15, 1052-1059.
43. Schatzberg, A. F. (2000). New indications for antidepressants. Journal of Clinical Psychiatry, 61, 9-17.
44. Schmidt, S., & Schmitz-Buhl, M. (1995). Signs and symptoms of carbamazepine overdose. Journal of Neurology, 242, 169-173.
45. Schreinzer, D., Frey, R., Stimpfl, T., Vycudilik, W., Berzlanovich, A., & Kasper, S. (2001). Different fatal toxicity of neuroleptics identified by autopsy. European Neuropsychopharmacology, 11, 117-124.
46. Schulz, S. C., Camlin, K. L., Berry, S. A., & Jesberger, J. A. (1999). Olanzapine safety and efficacy in patients with borderline personality disorder and comorbid dysthymia. Biological Psychiatry, 46, 1429-1435.
47. Soloff, P. H. (1994). Is there any drug treatment of choice for the borderline patient? Acta Psychiatrica Scandinavica, 89, 50-55.
48. Soloff, P. H. (2000). Psychopharmacology of borderline personality disorder. The Psychiatric Clinics of North America, 23, 169-192.
49. Southwick, S. M., Yehuda, R., Giller, E. L., & Perry, B. D. (1990). Altered platelet alpha2 adrenergic receptor binding sites in borderline personality disorder. American Journal of Psychiatry, 147, 1014-1017.
50. Stein, D. J., Simeon, D., Frenkel, M., Islam, M. N., & Hollander, E. (1995). An open trial of valproate in borderline personality disorder. Journal of Clinical Psychiatry, 56, 506-510.
51. Volavka, J., Czobor, P., Sheitman, B., Lindenmayer, J. P., Citrome, L., McEvoy, J. P., Cooper, T. B., Chakos, M., & Lieberman, J. A. (2002). Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. American Journal of Psychiatry, 159, 255-262.
52. Winchel, R., & Stanley, M. (1991). Self-injurious behavior: A review of the behavior and biology of self-mutilation. American Journal of Psychiatry, 148, 306-317.
53. Zanarini, M. C., & Frankenburg, F. R. (2001). Olanzapine treatment of female borderline personality disorder patients: A double-blind, placebo-controlled pilot study. Journal of Clinical Psychiatry, 62, 849-854.